Tumor lysis syndrome (TLS) in acute myeloid leukemia (AML) patients treated with azacitidine (AZA) and venetoclax (VEN).

被引：0
|
作者：
Huang, Joanna Q.
Academia, Emmeline
Pollyea, Daniel Aaron
Gutman, Jonathan Aaron
Hammes, Andrew
Chase, Stephanie
O'Bryant, Cindy L.
Kaiser, Jeff
机构：
[1] Univ Colorado Hosp, Aurora, CO USA
[2] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA
[3] Univ Colorado, Sch Med, Div Hematol, Aurora, CO USA
[4] Univ Colorado, Sch Med, Ctr Innovat Design & Anal, Dept Biostat & Informat, Aurora, CO USA
[5] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19507
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 2 study of azacitidine (AZA) and venetoclax (VEN) as maintenance therapy for acute myeloid leukemia (AML) patients in remission.
    Bazinet, Alexandre
    Kantarjian, Hagop M.
    Borthakur, Gautam
    Yilmaz, Musa
    Bose, Prithviraj
    Jabbour, Elias
    Valero, Yesid Alvarado
    Chien, Kelly Sharon
    Pemmaraju, Naveen
    Takahashi, Koichi
    Short, Nicholas James
    Daver, Naval Guastad
    Issa, Ghayas C.
    Jain, Nitin
    Bull-Linderman, Debra
    Dinardo, Courtney Denton
    Garcia-Manero, Guillermo
    Sasaki, Koji
    Ravandi, Farhad
    Kadia, Tapan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E19018 - E19018
  • [2] Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen
    Rowe, Margaret
    Babushok, Daria
    Carroll, Martin
    Carulli, Alison
    Frey, Noelle
    Gill, Saar
    Hexner, Elizabeth
    Hirsh, Rebecca
    Hossain, Nasheed
    Lai, Catherine
    Loren, Alison
    Luger, Selina
    Maillard, Ivan
    Mccurdy, Shannon
    Matthews, Andrew
    Martin, Mary Ellen
    Paralkar, Vikram R.
    Perl, Alexander
    Porter, David
    Pratz, Keith
    Stadtmauer, Edward
    Bruno, Ximena Jordan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (04) : 626 - 635
  • [3] Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia
    Arora, Sankalp
    Zainaldin, Carl
    Bathini, Srilakshmi
    Gupta, Udita
    Worth, Sarah
    Bachiashvili, Kimo
    Bhatia, Ravi
    Godby, Kelly
    Jamy, Omer
    Rangaraju, Sravanti
    Diamond, Barry
    Oliver, Josh D.
    Salzman, Donna
    Di Stasi, Antonio
    Vachhani, Pankit
    LEUKEMIA RESEARCH, 2022, 117
  • [4] Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL.
    Davids, Matthew Steven
    Seymour, John Francis
    Roberts, Andrew Warwick
    Eichhorst, Barbara
    Kipps, Thomas J.
    Mato, Anthony R.
    Stilgenbauer, Stephan
    Mobasher, Mehrdad
    Desai, Monali Bhardwaj
    Potluri, Jalaja
    Pena, German E.
    Verdugo, Maria E.
    Nielsen, Jacqueline
    Cyr, Aimee
    Fleming, Leanne Lash
    Hallek, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Findings From an Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia (AML), Including AML-M4 and AML-M5, Treated With Venetoclax (Ven) Plus Azacitidine (Aza)
    Konopleva, Marina
    DiNardo, Courtney
    Sun, Yan
    Loghavi, Sanam
    Jung, Paul
    Potluri, Jalaja
    Dail, Monique
    Chyla, Brenda
    Pollyea, Daniel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S266 - S267
  • [6] Siremadlin in Combination with Venetoclax (VEN) Plus Azacitidine (AZA) in Adult Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy: A Phase Ib/II Trial
    Daver, Naval
    Wei, Andrew H.
    Stein, Eytan
    DeAngelo, Daniel J.
    Pathak, Dhrubajyoti
    Xu, Yunnan
    Grzesiak, Stephanie
    Venditti, Adriano
    BLOOD, 2022, 140 : 11625 - 11627
  • [7] Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML)
    Fleming, Shaun
    Roboz, Gail J.
    Fathi, Amir T.
    Zhang, Tian Y.
    Wei, Andrew
    Carraway, Hetty E.
    Holes, Leanne
    Petrlik, Erica
    Prebet, Thomas
    Menezes, Daniel L.
    Bluemmert, Iryna
    Sun, Hao
    Ravandi, Farhad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S293 - S293
  • [8] Safety and Efficacy of Venetoclax (VEN) in Combination With Decitabine or Azacitidine in Treatment-Naive, Elderly Patients (≥65 Years) With Acute Myeloid Leukemia (AML)
    Pratz, K.
    Pollyea, D.
    Jonas, B.
    Pullarkat, V.
    Wei, A.
    Arellano, M.
    Becker, P.
    Frankfurt, O.
    Thirman, M.
    Pigneux, A.
    Recher, C.
    Seymour, J.
    Dvorak, N.
    Xu, T.
    Humerickhouse, R.
    Mabry, M.
    Potluri, J.
    Letai, A.
    DiNardo, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 11 - 12
  • [9] Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Itzykson, Raphael
    Thepot, Sylvain
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    BLOOD, 2010, 116 (21) : 199 - 199
  • [10] SAFETY AND EFFICACY OF VENETOCLAX (VEN) IN COMBINATION WITH DECITABINE OR AZACITIDINE IN TREATMENT-NAIVE, ELDERLY PATIENTS (≥65 YEARS) WITH ACUTE MYELOID LEUKEMIA (AML)
    Pratz, K.
    Pollyea, D. A.
    Jonas, B. A.
    Pullarkat, V.
    Wei, A.
    Arellano, M.
    Becker, P. S.
    Frankfurt, O.
    Thirman, M.
    Pigneux, A.
    Recher, C.
    Seymour, J. F.
    Dvorak, N.
    Xu, T.
    Humerickhouse, R.
    Mabry, M.
    Potluri, J.
    Letai, A.
    DiNardo, C.
    HAEMATOLOGICA, 2017, 102 : 175 - 176
12345